Loading stock data…
$24.00+0.61 (+2.61%)
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Xencor, Inc. in the Healthcare sector is trading at $24.00 with a market capitalization of $1.5B. Wall Street consensus targets $31.42 (12 analysts), implying a +30.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $30.61, remaining 47.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.22M↑ | $4.52M↓ | $28.24M↑ | $21.00M↓ | $43.61M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.07M↑ | -$77.86M↓ | -$53.63M↓ | -$47.52M↓ | -$33.17M |
| Net Income | -$21.73M↑ | -$128.92M↓ | -$6.65M↓ | -$6.03M↑ | -$30.82M |
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...